CA2325342A1 - Ligands doubles du recepteur avb3 et du recepteur associe aux metastases - Google Patents

Ligands doubles du recepteur avb3 et du recepteur associe aux metastases Download PDF

Info

Publication number
CA2325342A1
CA2325342A1 CA002325342A CA2325342A CA2325342A1 CA 2325342 A1 CA2325342 A1 CA 2325342A1 CA 002325342 A CA002325342 A CA 002325342A CA 2325342 A CA2325342 A CA 2325342A CA 2325342 A1 CA2325342 A1 CA 2325342A1
Authority
CA
Canada
Prior art keywords
compound
gly
asp
ala
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002325342A
Other languages
English (en)
Inventor
Foe S. Tjoeng
Kam F. Fok
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2325342A1 publication Critical patent/CA2325342A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur des composés pharmaceutiques ligands doubles du récepteur a¿v?b¿3? et du récepteur associé aux métastases, sur l'utilisation de ces ligands doubles, seuls ou en association avec d'autres agents, dans des préparations pharmaceutiques, et sur des méthodes de traitement d'états induits par l'a¿v?b¿3? et du cancer et d'autres maladies angiogènes telles que la rétinopathie diabétique, l'arthrite, les hémangiomes et le psoriasis.
CA002325342A 1998-04-08 1999-04-07 Ligands doubles du recepteur avb3 et du recepteur associe aux metastases Abandoned CA2325342A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8107498P 1998-04-08 1998-04-08
US60/081,074 1998-04-08
PCT/US1999/004295 WO1999051638A1 (fr) 1998-04-08 1999-04-07 LIGANDS DOUBLES DU RECEPTEUR Avb3 ET DU RECEPTEUR ASSOCIE AUX METASTASES

Publications (1)

Publication Number Publication Date
CA2325342A1 true CA2325342A1 (fr) 1999-10-14

Family

ID=22161939

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002325342A Abandoned CA2325342A1 (fr) 1998-04-08 1999-04-07 Ligands doubles du recepteur avb3 et du recepteur associe aux metastases

Country Status (5)

Country Link
EP (1) EP1070085A1 (fr)
JP (1) JP2002510709A (fr)
AU (1) AU3545399A (fr)
CA (1) CA2325342A1 (fr)
WO (1) WO1999051638A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009143A1 (fr) * 1998-08-13 2000-02-24 G.D. Searle & Co. Ligands multivalents du recepteur de avb3 et des recepteurs associes aux metastases
AU2001285919B2 (en) 2000-09-05 2007-08-23 Jiangsu Simcere Pharmaceutical R&D Co., Ltd Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen
WO2002066512A1 (fr) * 2001-02-16 2002-08-29 E.I. Dupont De Nemours And Company Tripeptides inhibiteurs de l'angiogenese, compositions, et leurs procedes d'utilisation
EP1238678A1 (fr) * 2001-03-08 2002-09-11 Bayer Aktiengesellschaft Conjugués d'agents cytostatiques et de ligands d'intégrine activés par des enzymes
HU230901B1 (hu) * 2001-07-10 2019-01-28 Ge Healthcare Limited Peptidalapú vegyületek és ezeket tartalmazó gyógyszerkészítmények
ES2384235T3 (es) * 2001-10-22 2012-07-02 The Scripps Research Institute Compuestos dirigidos a integrinas
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US10201616B2 (en) 2016-06-07 2019-02-12 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
EP0773441B1 (fr) * 1995-09-11 2000-08-02 La Jolla Cancer Research Foundation Molécules qui s'adressent in vivo vers un organe ou tissu prélevé et méthodes pour leur identification

Also Published As

Publication number Publication date
WO1999051638A1 (fr) 1999-10-14
EP1070085A1 (fr) 2001-01-24
AU3545399A (en) 1999-10-25
JP2002510709A (ja) 2002-04-09

Similar Documents

Publication Publication Date Title
JP4332163B2 (ja) Ｍｐｌ受容体に結合し血小板生成活性を有する二量体トロンボポエチンペプチド模倣体
EP1705248A1 (fr) Protéines de fusion comprenant une fraction d'angiostatine et leur utilisation dans un traitement ant-tumeur
US8759285B2 (en) VEGF superagonists and methods of use
RU2515063C9 (ru) Мутеины липокалина слезной жидкости, обладающие аффинностью к с-мет рецепторной тирозинкиназе человека, и способы их получения
US20060172941A1 (en) Anti-angiogenic peptides and methods of use thereof
CZ2001643A3 (cs) Exprese a export inhibitorů angiogeneze ve formě imunofúzinů
US20110076234A1 (en) Peptides comprising an isodgr motif
JP2003530070A (ja) Ｆｃ融合タンパク質としてのインターフェロン−αタンパク質の発現および搬出
WO1990013306A2 (fr) Petits polypeptides
JPH06509551A (ja) Ｇｐ　ＩＩ↓ｂＩＩＩ↓ａに対する高い特異性を有する血小板凝集阻害剤
HK1042434A1 (en) Polymer conjugates of interferon beta-1a and uses
JP2008231107A (ja) 抗血管新生性ポリペプチド及び血管新生を抑制するための方法
EP1070085A1 (fr) LIGANDS DOUBLES DU RECEPTEUR A v?b 3? ET DU RECEPTEUR ASSOCIE AUX METASTASES
CA2837858A1 (fr) Blocage de proteases inflammatoires par des theta - defensines
BG107214A (bg) Пептид, модулиращ тромбопоетиновия рецептор
JP2007506795A (ja) ボツリヌス菌ｃ３エキソトランスフェラーゼ組成物及び腫瘍の拡大を治療するための方法
CA2355874A1 (fr) Inhibiteurs de l'integrine $g(a)v$g(b)6
US20090092581A1 (en) Interferons of rhesus and cynomolgus origin and uses thereof
CA2338283A1 (fr) Ligands multivalents du recepteur de avb3 et des recepteurs associes aux metastases
MXPA03009082A (es) Variantes polipeptidicas de interferon gamma.
CA2601271A1 (fr) Proteines de fusion activatrices du plasminogene cible utilisees en tant qu'agents thrombolytiques
JP2000095702A (ja) サルモシンを有効成分として含む抗ガン剤
CN103044554B (zh) 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
JP2008532505A (ja) 二量体または多量体のマイクロタンパク質
US20040052810A1 (en) Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20050407